Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.
Ocugen’s updated fair value estimate has shifted from US$10.36 to US$11.57, putting recent analyst work into a slightly higher price target range. Analysts are tying this move to fresh research around its retinal gene therapy programs, where new data readouts and coverage initiations are feeding directly into revised models, even as opinions differ on timing and execution risk. Read on to see how these changing targets fit into the broader Ocugen story and what to watch as the narrative evolves.
Stay updated as the Fair Value for Ocugen shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Ocugen.
-
Oppenheimer sees Ocugen as an emerging gene therapy player in blinding ocular disorders, with lead asset OCU400 already in Phase 3 for retinitis pigmentosa, which supports its US$10 price target.
-
Canaccord starts coverage with a Buy rating and a US$12 price target, pointing to three clinical stage retinal programs and describing early data across all three as interesting.
-
Lucid Capital lifts its price target to US$22 from US$15 after preliminary Phase 2 data for OCU410 in geographic atrophy, signaling that new clinical readouts are feeding into higher modeled value.
-
Recent target increases from H.C. Wainwright and Noble Capital suggest a cluster of upward revisions as more research focuses on Ocugen’s retinal gene therapy pipeline and potential rare disease market reach.
-
Canaccord explicitly flags Q3 data as a possible de risking event, which underlines that execution and clinical outcomes remain key uncertainties for current valuations.
-
Oppenheimer’s thesis hinges on OCU400’s progress in a poorly met rare disease market, so setbacks in Phase 3 timing, study design, or regulatory feedback could materially affect the risk reward trade off analysts are modeling.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives!
We’ve flagged 4 risks for Ocugen. See which could impact your investment.
-
Ocugen reported 12 month Phase 2 ArMaDa data for OCU410 in geographic atrophy, showing a 31% reduction in lesion growth at the medium dose and a 27% slower rate of ellipsoid zone loss versus control. The company plans to start a Phase 3 registrational trial in the third quarter of 2026.
-
The company completed enrollment in the OCU400 Phase 3 liMeliGhT trial in retinitis pigmentosa. This is a one year study of 140 patients that is expected to support a rolling BLA filing in the third quarter of 2026 and potential U.S. and EU submissions from the same dataset.
-
Auditor PricewaterhouseCoopers LLP issued an unqualified opinion with a going concern emphasis in Ocugen’s 10 K for 2025, citing doubt about the company’s ability to continue as a going concern.
-
Ocugen raised US$22.5m through a registered direct equity offering at US$1.50 per share and secured 45 day lock up agreements on more than 300m shares and related instruments held by directors and officers. The stock was also added to the S&P Biotechnology Select Industry Index.